Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Cocrystal Pharma Inc
Healthcare
P/NCAV
0.62x
Ticker
COCP
Exchange
NASDAQ
Country
United States
Close
1.56 $
Mkt Cap
15.1M $
EV
-11.3M $
NCAV Burn Rate
37.8%
Current Ratio
8.92
Debt/Equity
0.0
EV/REV
N/Ax
EV/EBIT
0.6x
EV/FCF
0.8x
Dilution
30.0% p.A
Total Net Income
-303.6M $
Cheapness
84.0%
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses causing acute and chronic viral diseases. It has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. It also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average